Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006203 · ClinicalTrials.gov registry record · Phase 4
Naltrexone, Craving, and Drinking
A Phase 4 study of Alcoholism, sponsored by Brown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT00006203: Completed Phase 4 study of Alcoholism, sponsored by Brown University.
NCT00006203 is a Phase 4 study of Alcoholism that has completed, run by Brown University. The registered enrollment target is 180 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006203, a Phase 4 study of Alcoholism, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions. Participants will monitor and record their daily desires to drink, environmental circumstances in which urges occur, and drinking behavior using a palm top computer. Participants will receive naltrexone or a placebo. One week after receiving medication, all participants will be asked to respond to alcohol-related cues that may or may not arouse the desire to drink.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone 50 Mg
Study Locations (1)
Rhode Island
- Center for Alcohol and Addiction Studies, Brown University - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT00006203 record still lists
NCT00006203 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00006203 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00006203 about?
NCT00006203 is a clinical study titled "Naltrexone, Craving, and Drinking". This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions. Participants will monitor and record their daily desires to drink, environmental circumst...
What is the current status of trial NCT00006203?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. Estimated completion is 2005-05.
What conditions does trial NCT00006203 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00006203?
The interventions under investigation include: Placebo (DRUG), Naltrexone 50 Mg (DRUG).
Who is sponsoring clinical trial NCT00006203?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006203 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006203's enrollment target sits among peer trials
180 21st of 65 higher than 45 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Sertraline Pharmacotherapy for Alcoholism Subtypes
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
-
Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer